Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Arcus Biosciences, Inc. (RCUS)

NewAmsterdam Pharma Company N.V. and Arcus Biosciences, Inc. are both Biotechnology companies. Arcus Biosciences, Inc. is the larger, with a market value of $2.5B against $2.3B — 1.1× the size. NewAmsterdam Pharma Company N.V. grew revenue faster over the last twelve months: −26.4% against −58.3%. Arcus Biosciences, Inc. has the higher net margin (−453.0% vs −789.9%) and the higher return on invested capital (0.00% vs −23.1%). Across the 16 metrics below, NewAmsterdam Pharma Company N.V. leads on 9 and Arcus Biosciences, Inc. on 7.

Valuation

Metric NAMS RCUS Biotechnology median
P/E n/m n/m 10.26
P/S 91.08 22.77 9.18
P/B 3.75 6.36 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 66.59 17.49 8.98
Earnings yield (8.88%) (20.31%) (34.89%)
Free cash flow yield (6.39%) (20.51%) (24.52%)

Profitability

Metric NAMS RCUS Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (900.07%) (475.00%) 0.00%
Net margin (789.94%) (453.00%) 0.00%
Free cash flow margin (581.64%) (465.00%) 0.00%
Return on equity (30.16%) (114.11%) (50.12%)
Return on assets (27.79%) (50.56%) (45.60%)
Return on invested capital (23.13%) 0.00% 0.00%

Growth

Metric NAMS RCUS Biotechnology median
Revenue growth (TTM) (26.41%) (58.33%) 6.26%
EPS growth (last fiscal year) 32.81% (4.78%) 29.88%
Revenue growth, 5-year CAGR — 25.93% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS RCUS Biotechnology median
Debt to equity 0.00 0.28 0.00
Current ratio 11.76 3.34 4.89
Net debt to EBITDA 2.83 2.27 1.01

Dividend

Metric NAMS RCUS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NAMS RCUS Biotechnology median
Market cap 2.26b 2.51b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack